Alligator back for more, expands CRO collaboration with Theradex

By Flora Southey contact

- Last updated on GMT


Related tags: Cancer

Alligator Bioscience says an existing agreement with Theradex informed its decision to re-sign the CRO, this time to test metastatic cancer candidate ATOR-1015.

ATOR-1015 is a tumor-directed CTLA-4 antibody that targets the CTLA-4 and OX40 receptors, designed to work in combination with PD-1/PD-L1 therapies.

“We have worked previously with the Theradex London office on the ADC-1013 clinical phase I trial and were very pleased with their extensive expertise and high-quality delivery,” ​said spokesperson Cecilia Hofvander.

“We are looking forward to a likewise successful collaboration on ATOR-1015,” ​she added.

The trials – expected to begin in the second half of this year – will take place across five sites in Sweden and Denmark.


Hofvander said the immune activating effect of ATOR-1015 – directed towards the tumor since both targets CTLA-4 and OX40 are upregulated in the tumor microenvironment – could strongly reduce immune-related adverse effects.

Further, CTLA-4 is the only target that has shown clinical synergy with PD-1 to date, but this combination is unfortunately severely hampered by toxicity.

“We believe that ATOR-1015 can add CTLA-4 efficacy with far less toxicity, which would allow for combination with PD-1 therapy in a much larger population,” ​she said. 

Clinical challenges?

Alligator said it does not anticipate any particular challenges, beyond those of a typical immuno-oncology clinical trial.

“Recruitment is always a critical factor, but we have very good experience of recruitment from our clinical sites using similar inclusion and exclusion criteria and are confident that this will be managed successfully,” ​Hofvander told us.

Related topics: Clinical Development, Phase I-II

Related news

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us


View more